NCT00540072View on ClinicalTrials.gov

Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

July 30, 2001

Primary Completion Date

February 27, 2002

Study Completion Date

February 27, 2002

Conditions
Pneumonia, Bacterial
Interventions
DRUG

daptomycin

All Listed Sponsors
lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT00540072 - Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae | Biotech Hunter | Biotech Hunter